HIV | Penta

25

Mar, 2021

Advancing the delivery of HIV Care

Tags: HIV

On June 21-22, the International Workshop on Innovation in the delivery of HIV care will take place virtually. This is an important workshop highlighting the need for flexibility and innovation when it comes to caring for people living with HIV, to circumvent occurrences beyond our control that could negatively impact the type of care and treatment that healthcare workers provide. Participants will have the chance to share and learn how their peers provide care in terms of the innovative measures they introduced due to COVID-19, how they deliver HIV Care […]

22

Mar, 2021

Because we all have to grow up”: supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently

Tags: HIV

Authors: Chloe Lanyon, Janet Seeley, Stella Namukwaya, Victor Musiime, Sara Paparini, Helen Nakyambadde, Christine Matama, Anna Turkova, Sarah Bernays Published in: Journal of International Aids Society Abstract Introduction: Sustaining optimal adherence is the major challenge facing adolescents living with HIV (ALHIV), particularly in low-resource settings, where “second-line” is often the last accessible treatment option. We explored the knowledge and skills adolescents need in order to maintain improved adherence behaviours, and the specific ways clinicians and caregivers may support young people to do so more independently. Methods: We conducted individual, in-depth interviews with 20 ALHIV aged 10 to […]

12

Mar, 2021

Sharing our understanding of the immune response of children living with HIV

Tags: EPIICAL, HIV, CROI, Children

EPIICAL is proud to have presented four abstracts at the CROI conference this year, sharing updated information on viral decay and the immune response of children living with HIV who begin treatment early in life. EFFECT OF HIV ON IMMUNE ACTIVATION AND EXHAUSTION IN CD4 AND CD8 T CELLS IN INFANTS Stefano Rinaldi, Vinh B. Dinh, Suresh Pallikkuth, Lesley D. Armas, Nadia Sitoe, Rajendra Pahwa, Nicola Cotugno, Paula Vaz, Paolo Palma, MariaGrazia Lain, Savita G. Pahwa DYNAMICS OF INTACT PROVIRAL SEQUENCES IN EARLY TREATED HIV-1 CLADE C–INFECTED INFANTS Catherine […]

11

Mar, 2021

ODYSSEY trial finds new drug is better for treating children living with HIV

Tags: HIV, ODYSSEY, CROI, Children

The anti-HIV drug Dolutegravir improves outcomes for children with HIV infection when given in a 3-drug combination. These results come from the ODYSSEY trial which was presented yesterday at the Conference on Retroviruses and Opportunistic Infections. Dolutegravir has a number of potential advantages, including: Few drug-to-drug interactions, making it easier to use when treating people who need treatment for other conditions such as tuberculosis High potency at a low milligram dose, meaning tablets can be small High genetic barrier to resistance Low cost Trials of dolutegravir in combination treatments in […]

19

Feb, 2021

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

Tags: HIV, ART, Children

Authors: Cecilia L. Moore, Anna Turkova , Hilda Mujuru , Adeodata Kekitiinwa, Abbas Lugemwa, Cissy M. Kityo, Linda N. Barlow-Mosha, et al, ODYSSEY trial team Published in: BMC Infectious Diseases Background: Dolutegravir (DTG)-based antiretroviral therapy (ART) is highly effective and well-tolerated in adults and is rapidly being adopted globally. We describe the design of the ODYSSEY trial which evaluates the efficacy and safety of DTG-based ART compared with standard-of-care in children and adolescents. The ODYSSEY trial includes nested pharmacokinetic (PK) sub-studies which evaluated pragmatic World Health Organization (WHO) weight-band-based […]

3

Feb, 2021

Penta coordinates new European-African Project that will develop UNIVERSAL treatments for children living with HIV

Tags: HIV, UNIVERSAL, Penta Project

Penta is the coordinator for the newly funded EDCTP project – UNIVERSAL! Later in the day, we will be speaking with partners at the official kick-off meeting.

25

Jan, 2021

Paediatric HIV: we are not done yet!

Tags: HIV, AIDS, IAS

We met Martina Penazzato her and asked her thoughts on what urgent action we need to take to end AIDS in children.

21

Jan, 2021

EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir

Tags: HIV, ODYSSEY, Children

On 12 January 2021, the European Medicine Agency approved the use of dolutegravir 5mg dispersible tablets for treating HIV in young children living in Europe. This decision was based, in part, on data from our ODYSSEY trial, which we are conducting in close collaboration with the MRC CTU at the University College London. The EMA also authorised updating dosing recommendations for dolutegravir film-coated tablets (10mg, 25mg and 50mg) for children six years and older and weighing at least 14kg, bringing these in line with the World Health Organization weight bands. […]

20

Dec, 2020

Cheaper HIV treatment for children: a report in The Lancet

Tags: HIV, ODYSSEY

A new pricing agreement will bring the cost of treatment for children with HIV down from US$480 to less than $120.

10

Dec, 2020

Cascade of care in children and adolescents with HIV in the Russian Federation

Tags: HIV, Paediatric Medicines, REACH

The Cascade of Care, more commonly known as the HIV care continuum, is a calculation of how many people in a specific population diagnosed with HIV are initially linked to care, retained in care and have achieved viral suppression. It is an important tool in measuring success in controlling the HIV infection, identifying gaps in national HIV/AIDS strategies and set directions to improve care. On behalf of EPIICC and REACH researchers, Anna Turkova presented on the Cascade of Care of HIV positive children and adolescents in three Russian centres at […]

News

Advancing the delivery of HIV Care

Because we all have to grow up”: supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently

Sharing our understanding of the immune response of children living with HIV

ODYSSEY trial finds new drug is better for treating children living with HIV

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

Penta coordinates new European-African Project that will develop UNIVERSAL treatments for children living with HIV

Paediatric HIV: we are not done yet!

EU grants Marketing Authorisation to first-ever dispersible-tablet dolutegravir

Cheaper HIV treatment for children: a report in The Lancet

Cascade of care in children and adolescents with HIV in the Russian Federation

Because we all have to grow up”: supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently

DOLUTEGRAVIR-BASED ART IS SUPERIOR TO NNRTI/PI- BASED ART IN CHILDREN AND ADOLESCENTS

ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing

Harmonising regulatory approval for antibiotics in children